… the pathogenesis of Alzheimer’s disease (AD). We suggest that glutamate receptors of the
N-… It is likely that under such conditions Mg2+ ions, which block NMDA receptors under normal …

… Introduction: Despite recent advances in Alzheimer’s disease … receptor antagonist memantine
are currently the two approved symptomatic treatments for AD. 5-HT6 receptor antagonism …

… Potential role of muscarinic agonists in Alzheimer's disease. Drug Ther 1997;11: 450-59 [4] …
receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer's disease. …

… With the subsequent development of selective 5-HT 6 receptor antagonists, preclinical … this
receptor subtype in more detail. It is increasingly clear that blockade of 5-HT 6 receptors leads …

… Alzheimer's disease, suggesting for the first time that H 3 receptors are preserved in late-stage
disease… Functional antagonism of central H 3 receptors was demonstrated by blockade of …

Memantine, a partial antagonist of N-methyl-D-aspartate receptor (NMDAR), approved for
moderate to severe Alzheimer’s disease (AD) treatment within the US and Europe under …

… block virtually all NMDA receptor activity will very likely have unacceptable clinical side
effects. For this reason many previous NMDA receptor antagonists have disappointingly failed …

… different biological targets for Alzheimer’s disease. We have sought to combine, in the same
molecule, the neuroprotective action of N-methyl-d-aspartate receptor antagonism with the …

… acid (NMDA) receptor antagonist that combats the excessive activation of this receptor by its
… to the cognitive symptoms of the disease. Memantine may have additional nonsymptomatic …

… receptor antagonists in the treatment of AD. It has already been demonstrated that the
endothelin receptor antagonist … receptor antagonists may be beneficial in maintaining CBF in AD. …